Akebia Therapeutics (AKBA) Profit After Tax: 2016-2025
Historic Profit After Tax for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $540,000.
- Akebia Therapeutics' Profit After Tax rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
- Per Akebia Therapeutics' latest filing, its Profit After Tax stood at $540,000 for Q3 2025, which was up 118.62% from $247,000 recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Profit After Tax registered a high of $29.4 million during Q2 2022, and its lowest value of -$83.0 million during Q2 2021.
- In the last 3 years, Akebia Therapeutics' Profit After Tax had a median value of -$11.2 million in 2023 and averaged -$10.4 million.
- As far as peak fluctuations go, Akebia Therapeutics' Profit After Tax skyrocketed by 135.46% in 2022, and later crashed by 3,814.01% in 2024.
- Akebia Therapeutics' Profit After Tax (MRQ) stood at -$69.9 million in 2021, then skyrocketed by 91.31% to -$6.1 million in 2022, then skyrocketed by 110.11% to $614,000 in 2023, then plummeted by 3,814.01% to -$22.8 million in 2024, then skyrocketed by 102.37% to $540,000 in 2025.
- Its Profit After Tax was $540,000 in Q3 2025, compared to $247,000 in Q2 2025 and $6.1 million in Q1 2025.